123 related articles for article (PubMed ID: 26554912)
21. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
[TBL] [Abstract][Full Text] [Related]
22. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
23. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
[TBL] [Abstract][Full Text] [Related]
24. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
[TBL] [Abstract][Full Text] [Related]
25. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
Huang S; Ren X; Wang L; Zhang L; Wu X
Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
[TBL] [Abstract][Full Text] [Related]
26. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
27. In vivo destabilization and functional defects of the xeroderma pigmentosum C protein caused by a pathogenic missense mutation.
Yasuda G; Nishi R; Watanabe E; Mori T; Iwai S; Orioli D; Stefanini M; Hanaoka F; Sugasawa K
Mol Cell Biol; 2007 Oct; 27(19):6606-14. PubMed ID: 17682058
[TBL] [Abstract][Full Text] [Related]
28. Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
Okamoto T; Kohno M; Ito K; Takada K; Katsura M; Morodomi Y; Toyokawa G; Shoji F; Maehara Y
Anticancer Res; 2017 Apr; 37(4):1729-1735. PubMed ID: 28373435
[TBL] [Abstract][Full Text] [Related]
29. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
30. XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression.
Cui T; Srivastava AK; Han C; Yang L; Zhao R; Zou N; Qu M; Duan W; Zhang X; Wang QE
Oncotarget; 2015 Apr; 6(12):10060-72. PubMed ID: 25871391
[TBL] [Abstract][Full Text] [Related]
31. A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.
Hu H; Zhang L; Teng G; Wu Y; Chen Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():1641-9. PubMed ID: 26316738
[TBL] [Abstract][Full Text] [Related]
32. DNA mismatch repair deficiency accelerates lung neoplasm development in K-ras(LA1/+) mice: a brief report.
Downey CM; Jirik FR
Cancer Med; 2015 Jun; 4(6):897-902. PubMed ID: 25773971
[TBL] [Abstract][Full Text] [Related]
33. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
34. Mouse models of Kras activation in gastric cancer.
Won Y; Choi E
Exp Mol Med; 2022 Nov; 54(11):1793-1798. PubMed ID: 36369466
[TBL] [Abstract][Full Text] [Related]
35. AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.
Kim DG; Choi Y; Lee Y; Lim S; Kong J; Song J; Roh Y; Harmalkar DS; Lee K; Goo JI; Cho HY; Mushtaq AU; Lee J; Park SH; Kim D; Min BS; Lee KY; Jeon YH; Lee S; Lee K; Kim S
Nat Commun; 2022 May; 13(1):2572. PubMed ID: 35546148
[TBL] [Abstract][Full Text] [Related]
36. Natural small-molecules reverse Xeroderma Pigmentosum Complementation Group C (XPC) deficient-mediated drug-resistance in renal cell carcinoma.
Chen R; Lo HH; Yang C; Law BYK; Chen X; Lam CCI; Ho C; Cheong HL; Li Q; Zhong C; Ng JPL; Peter CKF; Wong VKW
Phytomedicine; 2024 Feb; 124():155310. PubMed ID: 38215574
[TBL] [Abstract][Full Text] [Related]
37. The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer.
Zhang J; Hu H; Xu S; Jiang H; Zhu J; Qin E; He Z; Chen E
Front Genet; 2020; 11():17. PubMed ID: 32117436
[TBL] [Abstract][Full Text] [Related]
38. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C; Andreani C; Vale G; Berto S; Melegari M; Crouch AC; Baluya DL; Kemble G; Hodges K; Starrett J; Politi K; Starnes SL; Lorenzini D; Raso MG; Solis Soto LM; Behrens C; Kadara H; Gao B; Wistuba II; Minna JD; McDonald JG; Scaglioni PP
Nat Commun; 2022 Jul; 13(1):4327. PubMed ID: 35882862
[TBL] [Abstract][Full Text] [Related]
39. Clinical prognostic significance of xeroderma pigmentosum group C and IFN‑γ in non‑small cell lung cancer.
Wang Y; Wang W; Wang H; Qin L; Zhang M; Zhang Y; Wang Y; Hao C; Qu M; Wang G
Oncol Lett; 2024 Jun; 27(6):259. PubMed ID: 38646492
[TBL] [Abstract][Full Text] [Related]
40. The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers.
Andrade F; German-Cortés J; Montero S; Carcavilla P; Baranda-Martínez-Abascal D; Moltó-Abad M; Seras-Franzoso J; Díaz-Riascos ZV; Rafael D; Abasolo I
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
